Diabete. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group1:
Caper oxymel including 2000 mg hydroalcoholic extraction of capparis spinosa in oxymel 30 cc per day orally in 2-3 divided doses for 3 month. Intervention 2: Inter
Treatment - Drugs
Placebo
Intervention group1:
Caper oxymel including 2000 mg hydroalcoholic extraction of capparis spinosa in oxymel 30 cc per day orally in 2-3 divided doses for 3 month
Intervention group2:
Simple suger oxymel 30 cc per day orally in 2-3 divided doses for 3 month
Control group:
Dextrose syroup (65%), 30 cc per day, orally in 2-3 divided doses for 3 month
Sponsors
Research and Technology Vice-Chancellory of Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Diabetic patients (type 2) whose disease has not been controlled inspit of taking complete oral medication based on ADA and they do not accept to take insulin? Ages between 30-65 years old? Definitive diagnosis of metabolic syndrom based on NECP:ATPIII diagnostic criteria exclusion criteria: Dissatisfaction with continuing participation? Necessity of any new therapeutic intervension during the study based on endocrinologist? Breast feeding and lactation? Complications such as increasing blood presure, chest pain, fatigue during treatment? Renal problem with increasing creatinine and decreasing GFR less than 60? Any systematic disease which influence on trend of disease such as cardiac diseases, liver problems and malignancies?Acute or sever complications of diabete such as DKA, hyperosmolar coma and sever hypoglycemia in recent 3 months? The critical illness which leads to hospitalisation in recent 3 months? Taking hyperglycemic agent such as immunosupressive and antileptic
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Waist circumference. Timepoint: Before in intervention, one month, two month and after intervention. Method of measurement: Using a tape in order to measure in cm.;Fasting blood suger. Timepoint: Before in intervention, one month, two month and after intervention. Method of measurement: Measuring by blood tests in mg/dl.;Lipid profil. Timepoint: Before and after intervention. Method of measurement: Measuring by blood tests in mg/dl.;HbA1c. Timepoint: Before and after intervention. Method of measurement: Measuring by blood tests in %.;Blood pressure. Timepoint: Before in intervention, one month, two month and after intervention. Method of measurement: Measuring by sphygmomanometer in mm/hg.;Microalbuminuria. Timepoint: Before and after intervention. Method of measurement: Measuring by urine tests in mg/l.;CRP. Timepoint: Before and after intervention. Method of measurement: Measuring by blood tests in mg/l. | — |
Secondary
| Measure | Time frame |
|---|---|
| SGOT. Timepoint: Before in intervention, one month, two month and after intervention. Method of measurement: Measuring by blood tests in IU/L.;SGPT. Timepoint: Before in intervention, one month, two month and after intervention. Method of measurement: Measuring by blood tests in IU/L.;ALP. Timepoint: Before in intervention, one month, two month and after intervention. Method of measurement: Measuring by blood tests in IU/L.;Creatinie. Timepoint: Before in intervention, one month, two month and after intervention. Method of measurement: Measuring by blood tests in mg/dl. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamideh Vahid
Faculty of Iranian Traditional Medicine and Complementary of Mashhad University of Medical Sciences
Outcome results
None listed